SOURCE: CDEX Inc.

May 08, 2008 09:00 ET

CDEX Announces the Addition of Heparin Signatures to ValiMed™ to Address Medication Errors and Contamination

The ValiMed™ Signature Library of 167 Signatures Now Has Seven Signatures of Heparin Such as Produced by Baxter Healthcare Corporation and Hospira Inc., Including Typical Neonatal and Pediatric Doses

TUCSON, AZ--(Marketwire - May 8, 2008) - CDEX Inc. (OTCBB: CEXI) announces that it now has seven heparin Signatures in its ValiMed™ Signature Library encompassing a range of concentrations and diluents, including typical neonatal and pediatric doses. (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.) ValiMed is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time. (For a complete list of the ValiMed Signatures, see www.cdex-inc.com.)

"Based on the recent medication errors and contamination events associated with heparin, our clients requested that we develop an expanded grouping of heparin Signatures for ValiMed," said Stuart Poteet, Manager of Marketing and Client Support. "The heparin Signatures developed are weighted heavily toward the neonatal and pediatric doses and will provide an increased measure of safety for the patients in hospitals using ValiMed. When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture. Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients. ValiMed can identify not only significant errors in medication and concentration, but also counterfeit or terrorist contaminated medications before they compromise the pharmaceutical supply chain."

About CDEX, Inc.

CDEX, a technology development company currently developing products using its patented/patent pending chemical detection technologies, is focused on (i) identification of substances of concern (e.g., explosives and illegal drugs, for security markets); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of compounded medication and detection of counterfeit or sub-par products, for the medical and brand protection markets). ValiMed™ and the Meth Scanner™ are CDEX solutions for the healthcare and security markets. Corporate headquarters and R&D facilities are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Pascal Pouligny ( ppouligny@cdex-inc.com) at 520.745.5172.

ANY NON-HISTORICAL STATEMENTS ARE FORWARD-LOOKING, AS DEFINED IN FEDERAL SECURITIES LAWS, AND GENERALLY CAN BE IDENTIFIED BY WORDS SUCH AS "EXPECTS," "PLANS," "MAY," "ANTICIPATES," "BELIEVES," "SHOULD," "INTENDS," "ESTIMATES," AND OTHER SIMILAR WORDS. THESE STATEMENTS POSE RISKS AND UNCERTAINTIES THAT CANNOT BE PREDICTED OR QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED. SUCH RISKS AND UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE EFFECTIVENESS, PROFITABILITY AND MARKETABILITY OF PRODUCTS, THE PROTECTION OF INTELLECTUAL PROPERTY AND PROPRIETARY INFORMATION, AND OTHER RISKS DETAILED FROM TIME-TO-TIME IN FILINGS WITH THE SEC. THERE IS NO OBLIGATION TO PUBLICLY UPDATE ANY FORWARD-LOOKING STATEMENTS.

Contact Information